FASN inhibitors have been shown to be effective in chemoprevention of breast cancer in HER2/neu transgenic mice, while other enzymes within the FA biosynthesis pathway have also been targeted experimentally and were shown to limit the growth and proliferation of cancer cells; such enzymes include ACC and SCD [72]. Here, ERBB2 is linked to breast carcinoma.